HK1257542A1 - 治療與cns水腫相關的損傷或狀況的方法 - Google Patents

治療與cns水腫相關的損傷或狀況的方法 Download PDF

Info

Publication number
HK1257542A1
HK1257542A1 HK18116503.6A HK18116503A HK1257542A1 HK 1257542 A1 HK1257542 A1 HK 1257542A1 HK 18116503 A HK18116503 A HK 18116503A HK 1257542 A1 HK1257542 A1 HK 1257542A1
Authority
HK
Hong Kong
Prior art keywords
subject
sur1
hours
injury
administering
Prior art date
Application number
HK18116503.6A
Other languages
English (en)
Chinese (zh)
Inventor
Sven Martin Jacobson
Original Assignee
生物切萨皮克有限责任公司
生物切薩皮克有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 生物切萨皮克有限责任公司, 生物切薩皮克有限責任公司 filed Critical 生物切萨皮克有限责任公司
Publication of HK1257542A1 publication Critical patent/HK1257542A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18116503.6A 2015-10-07 2016-10-07 治療與cns水腫相關的損傷或狀況的方法 HK1257542A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Publications (1)

Publication Number Publication Date
HK1257542A1 true HK1257542A1 (zh) 2019-10-25

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116503.6A HK1257542A1 (zh) 2015-10-07 2016-10-07 治療與cns水腫相關的損傷或狀況的方法

Country Status (15)

Country Link
US (4) US20180280325A1 (https=)
EP (1) EP3359162B1 (https=)
JP (4) JP7349786B2 (https=)
KR (2) KR102681027B1 (https=)
CN (2) CN108348534A (https=)
AU (3) AU2016335767B2 (https=)
BR (1) BR112018006925A2 (https=)
CA (1) CA3001321A1 (https=)
EA (1) EA201890893A1 (https=)
ES (1) ES2940669T3 (https=)
HK (1) HK1257542A1 (https=)
IL (1) IL258509B2 (https=)
MA (1) MA45574A (https=)
MX (1) MX392466B (https=)
WO (1) WO2017062765A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドAeromics,Inc. 新規方法
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
MA55813A (fr) * 2019-05-02 2022-03-09 Biogen Chesapeake Llc Procédé de traitement de sujets souffrant de contusions du système nerveux central
CN120004770A (zh) * 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) * 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
WO2009002832A2 (en) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
EP3339190A1 (en) * 2010-07-19 2018-06-27 Biogen Chesapeake LLC Containers for glyburide solutions
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema

Also Published As

Publication number Publication date
JP7810762B2 (ja) 2026-02-03
AU2022279369B2 (en) 2025-02-13
KR20180063296A (ko) 2018-06-11
IL258509B2 (en) 2023-04-01
CN108348534A (zh) 2018-07-31
EA201890893A1 (ru) 2018-09-28
EP3359162A4 (en) 2019-08-28
US20240216309A1 (en) 2024-07-04
JP2023053274A (ja) 2023-04-12
KR20240105519A (ko) 2024-07-05
JP2018530564A (ja) 2018-10-18
BR112018006925A2 (pt) 2018-10-16
KR102681027B1 (ko) 2024-07-02
MA45574A (fr) 2019-05-15
JP2024164167A (ja) 2024-11-26
MX2018004286A (es) 2018-08-09
MX392466B (es) 2025-03-24
US11951085B2 (en) 2024-04-09
AU2016335767B2 (en) 2022-10-06
US20220125750A1 (en) 2022-04-28
WO2017062765A1 (en) 2017-04-13
AU2025202620A1 (en) 2025-05-01
CN115737816A (zh) 2023-03-07
ES2940669T3 (es) 2023-05-10
AU2016335767A1 (en) 2018-05-24
AU2016335767A8 (en) 2018-06-28
AU2022279369A1 (en) 2023-01-19
JP7592768B2 (ja) 2024-12-02
US20180280325A1 (en) 2018-10-04
EP3359162A1 (en) 2018-08-15
JP2021073317A (ja) 2021-05-13
CA3001321A1 (en) 2017-04-13
JP7349786B2 (ja) 2023-09-25
IL258509B (en) 2022-12-01
US20250017880A1 (en) 2025-01-16
EP3359162B1 (en) 2022-12-21
IL258509A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP7592768B2 (ja) Cns浮腫に関連する損傷または状態を処置する方法
Carleton et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache
Peralta et al. Prophylactic intrathecal morphine and prevention of post–dural puncture headache: a randomized double-blind trial
Cenkowski et al. Hemodynamic effects of low-dose bupivacaine spinal anesthesia for cesarean section: A randomized controlled trial
Nivatpumin et al. Ephedrine versus ondansetron in the prevention of hypotension during cesarean delivery: a randomized, double-blind, placebo-controlled trial
JP2018530564A5 (https=)
AU2021213064A1 (en) Therapeutic uses of tirzepatide
EP4615451A1 (en) Uses of bupivacaine multivesicular liposomes as stellate ganglion block for treating anxiety disorders and traumatic brain injury
JP2026069546A (ja) Cns浮腫に関連する損傷または状態を処置する方法
CN113874002A (zh) 治疗患有中枢神经系统挫伤的受试者的方法
US20260115210A1 (en) Method for treating subjects suffering from central nervous system contusions
Natekar nursing Management of the Patient With a headache disorder
AbdelRady et al. Role of Granisetron in preventing hypotension after spinal anaesthesia with Levobupivacaine in rheumatic patients undergoing elective cesarean section: A randomized controlled trial
Tong et al. 13 Pain Emergencies and Complications of Pain Treatments